CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash Flows From Operating Activities:
Net loss	$ (1,121,918)	$ (783,901)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and Amortization	12,448	5,536
Changes in assets and liabilities:
Prepaid expenses and other receivables	93,889	(21,721)
Accounts payable and other liabilities	77,904	49,035
Prepayment to related party for clinical trials	249,459	(494,491)
Net cash used in operating activities	(688,218)	(1,245,542)
Cash Flows from Investing Activities:
Decrease in restricted cash	0	85,462
Purchase of property and equipment	(5,606)	(57,222)
Purchase of intangible assets	(50,334)	(7,181)
Net Cash used in investing activities	(55,940)	21,059
Cash Flows From Financing Activities:
Advances from related party	239,717	0
Net proceeds from issuance of common stock	10,000,000	0
Net cash provided by financing activities	10,239,717	0
Net increase (decrease) in cash	9,495,559	(1,224,483)
Effect of exchange rate changes on cash	988	(35,050)
Cash at beginning of period	354,749	1,873,141
Cash at end of period	$ 9,851,306	$ 613,608